Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1

Digestive Diseases and Sciences

Volumn 50, Issue 10, 2005, Pages 1804-1806

  Orlent, Hans ^a,e   Mathot, Ron A ^b   Van Bommel, Eric F ^c   Vulto, Arnold G ^b   Schalm, Solko W ^b   Brouwer, Johannes T ^d  

^a Sint Jan General Hospital   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^d REINIER DE GRAAF HOSPITAL   (Netherlands)

^e AZ Sint Jan ^*  (Belgium)

Author keywords

End stage renal failure; Hepatitis C; Membranoproliferative glomerulonephritis; Nephrotic syndrome; Peginterferon; Ribavirin

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LIVER BIOPSY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MONOTHERAPY; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; KIDNEY FAILURE; MIDDLE AGED; NEPHROTIC SYNDROME; RIBAVIRIN;

EID: 26244459878     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2941-x     Document Type: Article

References (11)

1. Johnson RJ, Gretch DR, Yamabe H, et al.: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328:465-170, 1993
2. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 36:S3-S20, 2002
3. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171, 2004
4. Fabrizi F, Poordad FF, Martin P: Hepatitis C infection and the patient with end-stage renal disease. Hepatology 36:3-10, 2002
5. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ: Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347:103-109, 2002
6. Cruzado JM: Recurrent glomerulonephritis and risk of renal allograft loss. N Engl J Med 347:1531-1532 (discussion 1531-1532), 2002
7. Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W: Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1:989-990, 1984
8. Glue P: The clinical pharmacology of ribavirin. Semin Liver Dis 19 (Suppl 1):17-24, 1999
9. Brachfeld A, Stahle L, Andersson J, Schvarcz R: Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 8:287-292, 2001
10. Tan AC, Brouwer JT, Glue P, et al.: Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 16:193-195, 2001
11. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L: Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 24:701-708, 2002